Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 16/20 | 0.74 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7725832 | 0.90 | SLC6A9 (0.78) | SLC6A9POLB | |
| SCHEMBL7731155 | 0.89 | SLC6A9 (0.77) | SLC6A9POLB | |
| SCHEMBL7731096 | 0.88 | SLC6A9 (0.69) | SLC6A9POLB | |
| SCHEMBL7720218 | 0.86 | SLC6A9 (0.84) | SLC6A9POLB | |
| SCHEMBL7725933 | 0.86 | SLC6A9 (0.67) | SLC6A9POLB | |
| SCHEMBL7724786 | 0.85 | SLC6A9 (0.87) | SLC6A9POLB | |
| SCHEMBL2856929 | 0.85 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL7727704 | 0.82 | SLC6A9 (0.74) | SLC6A9POLB | |
| SCHEMBL7724912 | 0.81 | SLC6A9 (0.67) | SLC6A9POLB | |
| SCHEMBL7720219 | 0.81 | SLC6A9 (0.72) | SLC6A9POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207155-B2 | Sulfonyl-azetidin-3-yl-methylamine amide analogs as GlyTl inhibitors, methods for making same, and use of same in treating psychiatric disorders | VANDERBILT UNIVERSITY (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207155-B2 | Sulfonyl-azetidin-3-yl-methylamine amide analogs as GlyTl inhibitors, methods for making same, and use of same in treating psychiatric disorders | VANDERBILT UNIVERSITY (US) | 2012-06-26 | — | — | US | disclosed |
| US-20100261696-A1 | SULFONYL-AZETIDIN-3-YL-METHYLAMINE AMIDE ANALOGS AS GLYT1 INHIBITORS, METHODS FOR MAKING SAME, AND USE OF SAME IN TREATING PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY | 2010-10-14 | — | — | US | disclosed |
| US-20100261696-A1 | SULFONYL-AZETIDIN-3-YL-METHYLAMINE AMIDE ANALOGS AS GLYT1 INHIBITORS, METHODS FOR MAKING SAME, AND USE OF SAME IN TREATING PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY | 2010-10-14 | — | — | US | disclosed |
| WO-2010114907-A1 | SULFONYL-AZETIDIN-3-YL-METHYLAMINE AMIDE ANALOGS AS GLYT1 INHIBITORS, METHODS FOR MAKING SAME, AND USE OF SAME IN TREATING PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261696-A1 | SULFONYL-AZETIDIN-3-YL-METHYLAMINE AMIDE ANALOGS AS GLYT1 INHIBITORS, METHODS FOR MAKING SAME, AND USE OF SAME IN TREATING PSYCHIATRIC DISORDERS | SLC1A2, SLC1A1, SLC18A2 | SLC6A9 23/4885CDK2 3187/4885AKT1 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.